Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 27, 2017

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 27, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, July 27, 2017
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

• Telephone 877-874-1568 (domestic) or 719-325-2484 (international); conference ID 4818690
• Webcast available at www.seattlegenetics.com in the Investors section

REPLAY access

• Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, July 27, 2017 through 5:00 p.m. PT on Monday, July 31, 2017 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 4818690
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs commercially available globally in 67 countries for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing enfortumab vedotin, an ADC for metastatic urothelial cancer, in a planned pivotal trial in collaboration with Astellas. Headquartered in Bothell, Washington, Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.